RU2625799C2 - ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ - Google Patents
ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ Download PDFInfo
- Publication number
- RU2625799C2 RU2625799C2 RU2014131390A RU2014131390A RU2625799C2 RU 2625799 C2 RU2625799 C2 RU 2625799C2 RU 2014131390 A RU2014131390 A RU 2014131390A RU 2014131390 A RU2014131390 A RU 2014131390A RU 2625799 C2 RU2625799 C2 RU 2625799C2
- Authority
- RU
- Russia
- Prior art keywords
- amino
- thieno
- carboxamide
- pyrimidine
- methylisoquinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2011-0146818 | 2011-12-30 | ||
| KR20110146818 | 2011-12-30 | ||
| PCT/KR2012/011571 WO2013100632A1 (en) | 2011-12-30 | 2012-12-27 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017124993A Division RU2705577C2 (ru) | 2011-12-30 | 2012-12-27 | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014131390A RU2014131390A (ru) | 2016-02-20 |
| RU2625799C2 true RU2625799C2 (ru) | 2017-07-19 |
Family
ID=48697978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014131390A RU2625799C2 (ru) | 2011-12-30 | 2012-12-27 | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ |
| RU2017124993A RU2705577C2 (ru) | 2011-12-30 | 2012-12-27 | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017124993A RU2705577C2 (ru) | 2011-12-30 | 2012-12-27 | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ |
Country Status (32)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2855267C2 (ru) * | 2021-03-26 | 2026-01-30 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные тетрагидротиенопиридина в качестве ингибиторов ddr |
| US12617801B2 (en) | 2021-03-26 | 2026-05-05 | Chiesi Farmaceutici S.P.A. | Tetrahydrothieno pyridine derivatives as DDRS inhibitors |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| KR20220051422A (ko) | 2014-10-14 | 2022-04-26 | 신젠타 파티서페이션즈 아게 | 1-(3,5-디클로로페닐)-2,2,2-트리플루오로에타논 및 그의 유도체의 제조 방법 |
| CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| CA3002558A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| SG11201803242TA (en) | 2015-10-29 | 2018-05-30 | Effector Therapeutics Inc | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 |
| WO2017087808A1 (en) | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
| CN106928252B (zh) * | 2015-12-31 | 2019-09-27 | 成都先导药物开发股份有限公司 | 一种抑制rock的化合物及其制备方法与应用 |
| CN108884096B (zh) | 2016-02-08 | 2022-03-22 | 豪夫迈·罗氏有限公司 | 作为ddr1抑制剂的螺二氢吲哚酮 |
| AU2017249229A1 (en) | 2016-04-15 | 2018-10-04 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CN106153920B (zh) * | 2016-07-25 | 2018-04-27 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018122746A1 (en) * | 2016-12-28 | 2018-07-05 | Minoryx Therapeutics S.L. | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| DK3582776T3 (da) | 2017-02-14 | 2024-01-08 | Effector Therapeutics Inc | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| ES2962961T3 (es) | 2017-07-28 | 2024-03-22 | Yuhan Corp | Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| JP7235748B2 (ja) * | 2017-11-30 | 2023-03-08 | ハンミ ファーム．カンパニー リミテッド | ４－アミノ－ｎ－（１－（（３－クロロ－２－フルオロフェニル）アミノ）－６－メチルイソキノリン－５－イル）チエノ［３，２－ｄ］ピリミジン－７－カルボキサミドの塩とその結晶形態 |
| BR112020010905A2 (pt) | 2017-11-30 | 2020-11-17 | Hanmi Pharm. Co., Ltd. | compostos, composição farmacêutica e uso de um composto ou da composiçao farmacêutica |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| EP3870178A4 (en) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | Crystalline forms of mnk inhibitors |
| WO2020106998A1 (en) | 2018-11-21 | 2020-05-28 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
| CN110183464B (zh) * | 2019-05-31 | 2021-08-31 | 淮阴工学院 | 一种抗癌化合物艾斯替尼及其合成方法和应用 |
| CA3178927A1 (en) | 2020-05-26 | 2021-12-02 | Hanmi Pharm. Co., Ltd. | Belvarafenib for use in cancer treatment |
| EP4178955A1 (en) | 2020-07-11 | 2023-05-17 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| US20230312556A1 (en) * | 2020-10-27 | 2023-10-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Arylamide compound, pharmaceutical composition comprising same, and preparation method therefor and use thereof |
| US20240002394A1 (en) * | 2020-11-24 | 2024-01-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Deuterium-modified thienopyridone compound |
| CN117940130A (zh) * | 2021-03-09 | 2024-04-26 | 基因泰克公司 | 用于脑癌治疗的贝伐拉非尼 |
| CN117561062A (zh) | 2021-04-06 | 2024-02-13 | 基因泰克公司 | 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法 |
| CN117202897A (zh) * | 2021-04-09 | 2023-12-08 | 基因泰克公司 | 使用raf抑制剂和pd-1轴抑制剂的组合疗法 |
| AU2022303488A1 (en) * | 2021-06-30 | 2024-01-04 | F. Hoffmann-La Roche Ag | Synthesis of a bis-mesylate salt of 4-amino-n-(1 -((3-chloro-2- fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide and intermediates thereto |
| CN114213430B (zh) * | 2021-12-28 | 2022-12-02 | 深圳湾实验室 | 4-氨基噻吩[3,2-d]嘧啶-7-羧酸的制备方法、蛋白激酶抑制剂中间体 |
| CN114524826A (zh) * | 2022-02-18 | 2022-05-24 | 郑州猫眼农业科技有限公司 | 7-溴-4-氯噻吩并[3,2-d]嘧啶的制备工艺 |
| JP2025507955A (ja) | 2022-03-02 | 2025-03-21 | ノバルティス アーゲー | 癌の治療のための精密療法 |
| US20260048075A1 (en) | 2022-08-10 | 2026-02-19 | Vib Vzw | Inhibition of TCF4/ITF2 in the Treatment of Cancer |
| CN117137855A (zh) * | 2023-08-31 | 2023-12-01 | 晨光生物科技集团股份有限公司 | 一种槐米饮片及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200802118A1 (ru) * | 2006-04-07 | 2009-04-28 | Девелоджен Ациенгезельшафт | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях |
| WO2011062372A2 (en) * | 2009-11-19 | 2011-05-26 | Korea Institute Of Science And Technology | 2, 4, 7 -substituted thieno [3, 2 -d] pyrimidine compounds as protein kinase inhibitors |
| WO2011093672A2 (en) * | 2010-01-29 | 2011-08-04 | Hanmi Pharm. Co., Ltd. | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase |
| WO2011093684A2 (en) * | 2010-01-29 | 2011-08-04 | Hanmi Holdings Co., Ltd. | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402518D0 (en) * | 2004-02-05 | 2004-03-10 | Astrazeneca Ab | Therapeutic agents |
| RU2525115C2 (ru) | 2004-06-24 | 2014-08-10 | Вертекс Фармасьютикалз Инкорпорейтед | Способ модуляции транспортеров атф-связывающей кассеты |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| MY146795A (en) | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| CN101563336A (zh) * | 2006-03-16 | 2009-10-21 | 诺瓦提斯公司 | 用于治疗特别是黑素瘤的杂环有机化合物 |
| WO2008044688A1 (en) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| AU2009248774B2 (en) | 2008-05-23 | 2012-05-31 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| CA2744713A1 (en) * | 2008-12-05 | 2010-06-10 | Arqule, Inc. | Raf inhibitors and their uses |
| WO2010101302A1 (en) * | 2009-03-05 | 2010-09-10 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as cdc7 kinase inhibitors |
| DE102009035754A1 (de) | 2009-07-24 | 2011-01-27 | Hartmetall-Werkzeugfabrik Paul Horn Gmbh | Schneideinsatz für ein Schneidwerkzeug zur spanenden Bearbeitung, insbesondere zum Hochvorschubfräsen |
| EP2470538A1 (en) | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
| KR101147550B1 (ko) * | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| JP5985473B2 (ja) * | 2010-07-13 | 2016-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体 |
-
2012
- 2012-12-27 SG SG11201402765TA patent/SG11201402765TA/en unknown
- 2012-12-27 IN IN6101DEN2014 patent/IN2014DN06101A/en unknown
- 2012-12-27 UA UAA201408629A patent/UA109614C2/ru unknown
- 2012-12-27 AU AU2012363558A patent/AU2012363558C1/en active Active
- 2012-12-27 US US15/783,240 patent/USRE47451E1/en active Active
- 2012-12-27 HR HRP20191840TT patent/HRP20191840T8/hr unknown
- 2012-12-27 RS RSP20191305 patent/RS59420B1/sr unknown
- 2012-12-27 LT LT12861811T patent/LT2797927T/lt unknown
- 2012-12-27 CA CA2859668A patent/CA2859668C/en active Active
- 2012-12-27 MX MX2019003468A patent/MX378640B/es unknown
- 2012-12-27 SI SI201231684T patent/SI2797927T1/sl unknown
- 2012-12-27 RU RU2014131390A patent/RU2625799C2/ru active
- 2012-12-27 CN CN201280064739.8A patent/CN104039798B/zh active Active
- 2012-12-27 DK DK12861811T patent/DK2797927T3/da active
- 2012-12-27 MY MYPI2014701742A patent/MY170988A/en unknown
- 2012-12-27 HU HUE12861811A patent/HUE045957T2/hu unknown
- 2012-12-27 AR ARP120105010A patent/AR089489A1/es active IP Right Grant
- 2012-12-27 PT PT128618113T patent/PT2797927T/pt unknown
- 2012-12-27 RU RU2017124993A patent/RU2705577C2/ru active
- 2012-12-27 EP EP12861811.3A patent/EP2797927B1/en active Active
- 2012-12-27 PL PL12861811T patent/PL2797927T3/pl unknown
- 2012-12-27 KR KR20120154061A patent/KR101490761B1/ko active Active
- 2012-12-27 WO PCT/KR2012/011571 patent/WO2013100632A1/en not_active Ceased
- 2012-12-27 EP EP19198802.1A patent/EP3617213B1/en active Active
- 2012-12-27 SG SG10201701999QA patent/SG10201701999QA/en unknown
- 2012-12-27 PE PE2014001048A patent/PE20141404A1/es active IP Right Grant
- 2012-12-27 JP JP2014550010A patent/JP5797345B2/ja active Active
- 2012-12-27 MX MX2014007230A patent/MX363659B/es unknown
- 2012-12-27 ES ES19198802T patent/ES3013322T3/es active Active
- 2012-12-27 ES ES12861811T patent/ES2751608T3/es active Active
- 2012-12-27 US US14/363,857 patent/US9156852B2/en not_active Ceased
- 2012-12-27 BR BR112014015720-0A patent/BR112014015720B1/pt active IP Right Grant
- 2012-12-27 BR BR122019019582-0A patent/BR122019019582B1/pt active IP Right Grant
- 2012-12-28 TW TW101151181A patent/TWI462927B/zh active
-
2014
- 2014-06-26 CL CL2014001729A patent/CL2014001729A1/es unknown
- 2014-06-27 PH PH12014501504A patent/PH12014501504B1/en unknown
- 2014-06-29 IL IL233441A patent/IL233441B/en active IP Right Grant
- 2014-07-25 CO CO14162082A patent/CO7010840A2/es active IP Right Grant
- 2014-07-29 ZA ZA2014/05583A patent/ZA201405583B/en unknown
-
2019
- 2019-04-28 IL IL266285A patent/IL266285B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200802118A1 (ru) * | 2006-04-07 | 2009-04-28 | Девелоджен Ациенгезельшафт | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях |
| WO2011062372A2 (en) * | 2009-11-19 | 2011-05-26 | Korea Institute Of Science And Technology | 2, 4, 7 -substituted thieno [3, 2 -d] pyrimidine compounds as protein kinase inhibitors |
| WO2011093672A2 (en) * | 2010-01-29 | 2011-08-04 | Hanmi Pharm. Co., Ltd. | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase |
| WO2011093684A2 (en) * | 2010-01-29 | 2011-08-04 | Hanmi Holdings Co., Ltd. | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2855267C2 (ru) * | 2021-03-26 | 2026-01-30 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные тетрагидротиенопиридина в качестве ингибиторов ddr |
| US12617801B2 (en) | 2021-03-26 | 2026-05-05 | Chiesi Farmaceutici S.P.A. | Tetrahydrothieno pyridine derivatives as DDRS inhibitors |
| RU2861342C2 (ru) * | 2021-06-30 | 2026-05-05 | Дженентек, Инк. | Синтез бис-мезилатной соли 4-амино-n-(1-((3-хлор-2-фторфенил)амино)-6-метилизохинолин-5-ил)тиено[3,2-d]пиримидин-7-карбоксамида и ее промежуточных соединений |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2705577C2 (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ | |
| US9388165B2 (en) | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | |
| US20230060973A1 (en) | Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase | |
| HK40025544A (en) | Thieno[3,2‑d]pyrimidine derivatives having inhibitory activity for protein kinases | |
| HK40025544B (en) | Thieno[3,2‑d]pyrimidine derivatives having inhibitory activity for protein kinases | |
| NZ628013B2 (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | |
| HK1200833B (en) | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases | |
| HK40033835B (en) | Thieno[3,2-d]pyrimidine compound having inhibitory activity for protein kinase | |
| AU2010313240A1 (en) | Kinase inhibitors |